The Domore! project - a presentation of the five-year long Lighthouse project financed by the Norwegian Research Council
After five years of collaboration with users, public partners and commercial players the Domore! project concluded in 2021. The final report describes results emerging from the project as well as challenges ahead.
PTEN and DNA Ploidy Status by Machine Learning in Prostate Cancer
Published in Cancers, Basel,
New investors for DoMore! Diagnostics
Norselab and Grotmol invest 15 mill nok in DoMore! Diagnostics, enabling further development and better treatment for cancer patients.
Patent application submitted
The CDoMore-v1-CRC is a marker aiding doctors and pathologists in giving a more precise prognosis for patients with colorectal cancer.
Designing deep learning studies in cancer diagnostics
If artificial intelligence-based technology for cancer diagnostics exists, why is it still not in use? How can new knowledge in deep learning and artificial intelligence in diagnostics benefit cancer patients in the fastest and safest way? Read our discussion of reasons behind the moderate progress and description for remedies designed to facilitate the transition from research to clinical use.
Artificial Intelligence in cancer treatment
Listen to Håvard E. Danielsen explaining Domore! and the use of artificial intelligence in cancer prognostication and diagnostics in thsi podcast from NORA (Norwegian Artificial Intelligence Research Consortium).
AI transformation of medical practices can go faster with better design of deep learning studies
- according to a Perspective from ICGI researchers.
The DoMore!-project has reached the chapter on commercialization. Inven2's project manager Elin Melby says she has great faith in the company's potential.
Deep learning for prediction of colorectal cancer outcome: a discovery and validation study
Published in the Lancet,
1st February 2020
Prognostic value of DNA ploidy and automated assessment of stroma fraction in prostate cancer
Published in the International Journal of Cancer,
Prognostic value of mitotic checkpoint protein BUB3, cyclin B1, and pituitary tumor-transforming 1 expression in prostate cancer
Published in Modern Pathology,
Association Between Proportion of Nuclei With High Chromatin Entropy and Prognosis in Gynecological Cancers
Published in the Journal of the National Cancer Institute, 18.04.2018
The Lancet article presented at Oslo Life Science 2020
10th February 2020
The DoMore! Mid-Term Report
At the end of 2018, we reached the mid-way point of the 5-year long project, and this report reflects the challenges and results so far.
Providing prognostication using AI-based markers as a diagnostic service
How AI can be used in Cancer Prognostics
Chromatin organisation and cancer prognosis: a pan-cancer study
Published in the Lancet Oncology, 02.02.2018
Clinical utility of chromatin analysis
Editorial in Oncotarget, 21.08.2018
How AI changes the prognostication of cancer
Kari Andresen, head of the Unit for Dissemination and Visualisation, has written an article about the DoMore! project.
7. June 2019
DoMore! presented at the launch of the National Health and Hospital Plan for 2020 and onward.
31. October 2019
DoMore! and AI presented at the Norwegian Oncology Forum 2019
Prognostic markers for colorectal cancer; estimating ploidy and stroma
Published in the Annals of Oncology, 01.02.2018
Tumour heterogeneity poses a significant challenge to cancer biomarker research
Published in the British Journal of Cancer, 25.07.2017